ArticleJAMA network open2025
Prevalence of Impairing Substance Use in Injured Drivers.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Detection of Δ9-Tetrahydrocannabinol Impairment Using Resting-State Functional Near-Infrared Spectroscopy: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Validation of a microsampling-compatible liquid-liquid extraction method for cannabinoid quantitation in 50 µL of whole blood using liquid chromatography-mass spectrometry.Journal of analytical toxicology · 2026Article
- Review of Selected 2-Phenylethylamine Derivatives and Opioids, Systematic Review of Their Effects on Psychomotor Abilities and Driving Performance: Psychopharmacology in the Context of Road Safety.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Importance: Impaired driving is an important public health issue, but its prevalence is challenging to monitor. Objectives: To report the prevalence of alcohol, cannabis, recreational drugs, and sedating medications in injured Canadian drivers, identify demographic and collision factors associated with drug or alcohol use, and compare the prevalence of drug-involved driving in different parts of Canada. Design, Setting, and Participants: This cross-sectional study prospectively obtained blood samples from injured drivers treated in 15 Canadian trauma centers and measured blood levels of tetrahydrocannabinol (THC; the main impairing compound in cannabis), alcohol, stimulants, opioids, and depressants from January 2019 to June 2023. Data were analyzed from April to May 2024. Exposure: Blood levels of THC, alcohol, stimulants, opioids, and depressants. Main Outcomes and Measures: Demographic and collision details were extracted from medical records. The crude prevalence for each substance class among all injured drivers and in selected subgroups was computed. Logistic regression models identified factors associated with substance use. Results: Of 8328 injured drivers (mean [SD] age, 43 [18] years; median [IQR] age, 40 [28-57] years; 5605 male [67.3%]; 2723 female [32.7%]), 4568 (54.9%) tested positive for an impairing substance and 1798 (21.6%) tested positive for 2 or more substance classes. Depressants, as a class, were detected in 2368 drivers (28.4%). THC was the most commonly detected single substance (1354 drivers [16.3%]), followed by alcohol (1341 drivers [16.1%]). Stimulants (1057 drivers [12.7%]) and opioids (905 drivers [10.9%]) were also detected. Substances were detected less often in drivers aged 75 years or older (195 of 455 drivers [42.9%]) and younger than 19 years (149 of 304 drivers [49.0%]). THC was most common in drivers aged 19 to 24 years, alcohol in drivers aged 19 to 34 years, stimulants in drivers aged 35 to 44 years, opioids in drivers aged 55 to 64 years, and depressants in drivers aged 65 to 74 years. Males had similar prevalence of substance use as females (3141 males [56.0%] vs 1427 females [52.4%]); more males used alcohol (adjusted odds ratio [aOR], 1.53; 95% CI, 1.21-1.92), cannabis (aOR, 1.66; 95% CI, 1.48-1.86), and stimulants (aOR, 1.53; 95% CI, 1.34-1.75), but males were less likely to have used a depressant (aOR, 0.54; 95% CI, 0.47-0.62). Rural drivers were more likely to use alcohol (aOR, 1.51; 95% CI, 1.29-1.76), stimulants (aOR, 1.32; 95 CI, 1.03-1.70), depressants (aOR, 1.28; 95% CI, 1.09-1.51), opioids (aOR, 1.26; 95% CI, 1.08-1.47), any substance (aOR, 1.40; 95% CI, 1.20-1.63), or multiple classes of substances (aOR, 1.55; 95 CI, 1.23-1.95). There was substantial geographic variation in the prevalence of substance use in injured drivers. Conclusions and Relevance: These findings suggest that impaired driving is a substantial road safety concern in Canada. Continued monitoring is required to develop targeted interventions and to evaluate the effectiveness of prevention measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.